# PEG-MGF Peptide

> PEG-MGF is a pegylated mechano-growth-factor fragment that targets muscle repair signaling, satellite-cell activity, and extended IGF-1Ec exposure.

Canonical: https://pepflow.app/peptides/peg-mgf/

The MGF Extension

PEG-MGF refers to a pegylated version of mechano growth factor, the IGF-1Ec E-domain peptide discussed in muscle and repair biology. PEGylation is intended to extend exposure compared with an unmodified peptide fragment.

Muscle repair  Training recovery

Tier E

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 22 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is PEG-MGF?

PEG-MGF refers to a pegylated version of mechano growth factor, the IGF-1Ec E-domain peptide discussed in muscle and repair biology. PEGylation is intended to extend exposure compared with an unmodified peptide fragment.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>)

The evidence problem is molecule specificity. Mechano growth factor and IGF-1 splice-variant literature can support biological plausibility, but it does not automatically validate commercial PEG-MGF products or injectable protocols.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>)

The name is often used in performance catalogs. That market usage needs separation from the peer-reviewed MGF literature, product identity, and anti-doping status.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) For more context, read the [PEG-MGF identity explainer](<https://pepflow.app/blog/what-is-peg-mgf/>).

## What PEG-MGF is investigated for

PEG-MGF evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Muscle growth and training recovery Injectable 32% Limited

PEG-MGF belongs in a preclinical muscle-repair rationale, not as a proven growth or recovery tool.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/21354439/>)

#### Human evidence

Direct controlled human PEG-MGF muscle-growth or training-recovery outcome trials are not established.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/21354439/>)

#### Animal / mechanistic evidence

MGF-E and IGF-1Ec studies support muscle progenitor-cell activation and tissue-repair plausibility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/21354439/>)

### ### Musculoskeletal tissue repair Injectable 28% Limited

Tissue-repair claims are mechanistic and disease-model dependent, with no direct clinical protocol signal.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39067248/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

#### Human evidence

Human musculoskeletal repair outcomes for PEG-MGF are not established in the reviewed sources.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39067248/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

#### Animal / mechanistic evidence

Cartilage and periodontal-ligament stem-cell publications support broader repair biology outside skeletal muscle.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/39067248/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

### ### Cardiac and motor-neuron protection Injectable 24% Limited

Cardiac and motor-neuron claims are separate from muscle growth and remain clearly preclinical.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/36467694/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

#### Human evidence

Human cardioprotection or neuroprotection outcome trials for PEG-MGF are not established.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/36467694/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

#### Animal / mechanistic evidence

MGF literature includes SOD1 mouse motor-neuron rescue and cardiac contractile-function biology.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/36467694/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)

## Evidence snapshot

### Overall confidence

Limited

30%

PEG-MGF remains a preclinical muscle-repair rationale rather than a proven performance peptide. The main gaps are product-specific human pharmacology, outcome data, and safety evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

### Human evidence

Insufficient

No controlled human PEG-MGF outcome evidence establishes muscle growth, repair, or training adaptation. Reader-facing confidence therefore depends on indirect MGF and IGF-1Ec literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

20%

### Animal / preclinical

Limited

MGF and IGF-1Ec studies support repair and regeneration plausibility in experimental systems. PEGylated-product translation is not settled.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

30%

### Mechanism support

Limited

MGF-related peptides are discussed around local tissue responses to mechanical stress and muscle-cell repair behavior. The peptide concept is mechanistic, not outcome-proven.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## Forms & administration

PEG-MGF is tracked as an injectable growth-factor-adjacent research peptide. Post-training protocol patterns are separate from prescription IGF or GH products.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 200-400 mcg per dose.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

### Frequency

Usually taken 2-3 times per week.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

### Timing Considerations

After a workout is the usual timing.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

### Cycle Length

Common cycles run 4-6 weeks.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

[Full PEG-MGF dosage guide](<https://pepflow.app/peptides/peg-mgf/dosage/>)

## What to expect

### First 1-2 weeks

Post-workout injectable PEG-MGF use may align with changes in muscle pump, soreness between sessions, and perceived recovery from loaded training.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>)

### Weeks 4-6

Injectable post-training blocks may show as clearer strength trends, training volume, soreness patterns, and limb-measurement changes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>)

### After stopping

Recovery and hypertrophy signals after injectable PEG-MGF depend mostly on whether training load, nutrition, and sleep remain consistent.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>)

## Safety profile

PEG-MGF safety is driven by growth-factor biology and injectable product identity rather than a mature human side-effect profile.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### Cautions

- Growth-factor pathway[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- PEGylated product identity[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Prohibited in sport[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### What we don't know

Human pharmacokinetics, immunogenicity, dose-response, and repeated-cycle safety remain poorly defined for PEG-MGF products.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Who PEG-MGF is not for

Route-specific avoid and medical-review notes:

- **Active malignancy**

  Active malignancy warrants medical review or avoidance for PEG-MGF.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)
- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for PEG-MGF.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)
- **Uncontrolled endocrine or metabolic disease**

  Uncontrolled endocrine or metabolic disease warrants medical review or avoidance for PEG-MGF.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **IGF / GH products**

  IGF analogs, somatropin, GH secretagogues, or MGF variants can stack growth-factor exposure and edema signals; this is a theoretical pathway caution.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **Anabolic hormones**

  Testosterone or anabolic agents can compound muscle-growth claims and fluid-retention signals; this is a theoretical pathway caution.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **Performance stacks**

  Performance stacks that combine multiple prohibited growth-factor products can add regulatory and product-quality uncertainty; this is a product-quality caution.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, PEG-MGF is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · PEG-MGF is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Flagged · FDA safety-risk materials flag PEG-MGF with significant immunogenicity, peptide-impurity, API-characterization, and missing human-exposure concerns. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Approved

PEG-MGF is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Flagged

FDA safety-risk materials flag PEG-MGF with significant immunogenicity, peptide-impurity, API-characterization, and missing human-exposure concerns. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[15\]](<https://www.ema.europa.eu/en/medicines>) [\[16\]](<https://products.mhra.gov.uk/>) [\[17\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[18\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S2 applies to growth factors and IGF-axis products; tested athletes should treat PEG-MGF as prohibited unless a valid TUE or anti-doping review applies.[\[10\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

PEG-MGF sits in the mechano-growth-factor story: an IGF-1 splice-variant E-domain concept tied to mechanical stress, muscle-cell behavior, cartilage biology, and repair signaling. In plain terms, the proposed target is local regeneration biology after tissue strain.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

PEGylation changes the mechanism question because it can extend exposure and alter immune or product-quality risk. Evidence for parent MGF or synthetic E-domain peptides does not prove that an injectable PEGylated product has the same benefit-risk balance in humans. Sterility and peptide aggregation risk are also part of the route-specific interpretation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## Research gaps & open questions

What the current literature has not yet settled about PEG-MGF:

01

Human studies need to establish how authentic PEG-MGF is absorbed, distributed, and cleared; results from MGF or IGF-1 should not be assumed to apply to the PEGylated fragment.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

02

Controlled trials need to show whether PEG-MGF actually improves muscle growth, strength, recovery, or healing after injury in people.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

03

Studies need to determine whether the PEG attachment or repeated exposure can trigger immune reactions or other long-term harm.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## Common questions

### Is PEG-MGF FDA-approved?

No. PEG-MGF is not FDA-approved in the U.S.; FDA lists it with significant compounding safety concerns.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

### Does MGF evidence prove PEG-MGF works?

No. Parent MGF biology supports repair plausibility, but PEGylation changes exposure and product-specific safety, so PEG-MGF needs its own evidence.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)

### Is PEG-MGF proven for muscle growth?

Not proven. Controlled human muscle-growth outcomes for injectable PEG-MGF are not established, and FDA lists PEG-MGF with compounding safety concerns.[\[8\]](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>) [\[9\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[12\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

## Myths & misconceptions

### Myth

PEG-MGF is the same as local MGF biology.

### Reality

PEGylation and injectable exposure can change interpretation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

### Myth

Training-day timing proves it is working.

### Reality

Timing customs are not the same as controlled outcome evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## History & discovery

PEG-MGF grew out of mechano-growth-factor work, where IGF-1 splice-variant biology was connected with mechanical load, muscle repair, cartilage, and regeneration. The PEGylated market product came later. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

MGF and IGF-1Ec studies gave the peptide a repair-and-regeneration rationale across muscle, motor-neuron, and cartilage models. That history supports plausibility, not product-level human efficacy.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

PEG-MGF entered catalog use as a longer-exposure version of MGF-style signaling. PEGylation changed the route and safety question, so parent-MGF findings do not settle injectable PEG-MGF outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/20130113/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/24776619/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/19038252/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)

## Published research 22 citations

- [\[1\] **Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.** Endocrinology, 2010 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/20130113/>)
- [\[2\] **Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides.** Hormones (Athens), 2014 Apr-Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/24776619/>)
- [\[3\] **Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.** Exp Neurol, 2009 Feb. animal.](<https://pubmed.ncbi.nlm.nih.gov/19038252/>)
- [\[4\] **The role of mechano growth factor in chondrocytes and cartilage defects: a concise review.** Acta Biochim Biophys Sin (Shanghai), 2023 May 12. review.](<https://pubmed.ncbi.nlm.nih.gov/37171185/>)
- [\[5\] **Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.** Mech Ageing Dev, 2011 Apr. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/21354439/>)
- [\[6\] **Mechano-growth factor regulates periodontal ligament stem cell proliferation and differentiation through Fyn-RhoA-YAP signaling.** Biochem Biophys Res Commun, 2024 Nov 12. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/39067248/>)
- [\[7\] **Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes.** Front Physiol, 2022. review.](<https://pubmed.ncbi.nlm.nih.gov/36467694/>)
- [\[8\] **Drugs@FDA/openFDA query for PEG-MGF** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22PEG-MGF%22&limit=1>)
- [\[9\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[10\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[11\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[12\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[13\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[14\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[15\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[16\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[17\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[18\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[19\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[20\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[21\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[22\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

E

**Evidence**

30% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Flagged

**Citations**

[22 citations](<https://pepflow.app/peptides/peg-mgf/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Muscle growth and training recovery
- Musculoskeletal tissue repair
- Cardiac and motor-neuron protection

### Also known as

- Pegylated mechano growth factor
- PEGylated MGF
- MGF
- IGF-1Ec E-peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [What Is PEG MGF: PEG MGF Explained](<https://pepflow.app/blog/what-is-peg-mgf/>)
- [PEG-MGF dosage guide](<https://pepflow.app/peptides/peg-mgf/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
